Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
A next-generation triple-agonist peptide (GIP/GLP-1/glucagon) currently studied for its potential to support more advanced weight management outcomes than earlier-generation therapies.
A next-generation triple-agonist peptide (GIP/GLP-1/glucagon) currently studied for its potential to support more advanced weight management outcomes than earlier-generation therapies.